Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01253902 · ClinicalTrials.gov registry record · Phase 4
Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension
A Phase 4 study of Ocular Hypertension and Glaucoma Open-Angle, sponsored by Allergan.
- Completed
- Registry status
- Phase 4
- Development phase
- 164
- Enrollment target
- 2
- Study locations
NCT01253902: Completed Phase 4 study of Ocular Hypertension and Glaucoma Open-Angle, sponsored by Allergan.
NCT01253902 is a Phase 4 study of Ocular Hypertension and Glaucoma Open-Angle that has completed, run by Allergan. The registered enrollment target is 164 participants, below the 275-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (40% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01253902, a Phase 4 study of Ocular Hypertension and Glaucoma Open-Angle, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 164 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study evaluated the ocular surface tolerability of the prostaglandin analogues bimatoprost ophthalmic solution 0.01% (Lumigan® 0.01%), travoprost ophthalmic solution 0.004% (Travatan Z®) and latanoprost ophthalmic solution 0.005% (Xalatan®) in patients previously treated with Xalatan® who have open-angle glaucoma or ocular hypertension.
Primary Outcome
Conjunctival hyperemia was analyzed using the average of the scores of both eyes. Hyperemia is engorgement of the blood vessels (redness) of the bulbar conjunctiva of the eye (the clear membrane covering the white surface of the eye). Hyperemia was graded on a 5 point scale where 0=none (normal), 0.5=trace (trace flush reddish pink), 1=Mild (mild flush reddish color), 2=Moderate (bright red color) and 3=severe (deep bright diffuse redness).
Conditions Studied
Interventions
- DRUG bimatoprost ophthalmic solution 0.01%
- DRUG travoprost ophthalmic solution 0.004%
- DRUG latanoprost ophthalmic solution 0.005%
Study Locations (2)
Arkansas
- - Rogers
Alberta
- - Calgary
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2010-12 |
| Est. Completion | 2011-10 |
| Phase | Phase 4 |
What the finished NCT01253902 record still lists
NCT01253902 is an interventional study that assigns participants to a tested intervention. The registered 164 participants enrollment target is mid-sized for trials with a published cap, below the 275-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (40% lower).
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 3 interventions - of which bimatoprost ophthalmic solution 0.01% is the first listed.
NCT01253902 reports a single indexed study location in Arkansas, Alberta.
Frequently Asked Questions
What is clinical trial NCT01253902 about?
NCT01253902 is a clinical study titled "Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension". This study evaluated the ocular surface tolerability of the prostaglandin analogues bimatoprost ophthalmic solution 0.01% (Lumigan® 0.01%), travoprost ophthalmic solution 0.004% (Travatan Z®) and latanoprost ophthalmic solution 0.005% (Xalatan®) in patients previously treated with Xalatan® who have ...
What is the current status of trial NCT01253902?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 164 participants. The study started on 2010-12. Estimated completion is 2011-10.
What conditions does trial NCT01253902 study?
This clinical trial studies the following conditions: Ocular Hypertension, Glaucoma Open-Angle.
What interventions are being tested in trial NCT01253902?
The interventions under investigation include: bimatoprost ophthalmic solution 0.01% (DRUG), travoprost ophthalmic solution 0.004% (DRUG), latanoprost ophthalmic solution 0.005% (DRUG).
Who is sponsoring clinical trial NCT01253902?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01253902 being conducted?
This trial has 2 study locations across Arkansas, Alberta. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01253902's enrollment target sits among peer trials
164 28th of 54 higher than 27 of 54 other Ocular Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ocular Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
RECRUITING · Phase 4
-
Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
RECRUITING · Phase 4
-
Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%
COMPLETED · Phase 4
-
Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)
COMPLETED · Phase 4
-
DSLT for Reducing Medication in Glaucoma
RECRUITING
-
24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04891289 · 164 participants · Phase 2
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
- NCT04893226 · 164 participants · NA
Time-Restricted Feeding Intervention in Metabolically-Unhealthy Postmenopausal Women
- NCT05270213 · 164 participants · Phase 1
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
- NCT05543681 · 164 participants · Phase 2
Clinical Trial on Agitation in Alzheimer's Dementia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia